Nuevos conceptos sobre hormonodependencia en el cancer de mama

Medicina

Volumn 57, Issue 1, 1997, Pages 95-103

  Levin, Emanuel ^a   Caruso, Silvana P ^a   Actis, Andrea M ^a   De Levin, Rosa W ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; ESTRADIOL; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER RESISTANCE; CELL PROLIFERATION; DRUG EFFICACY; GENETIC TRANSCRIPTION; HUMAN; MODULATION; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 0030964160     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Russo J, Tay LK, Russo HI. Differentiation of the mammary gland and suceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2: 5-73.
2. Freiss G, Pébois C, Vignon F. Control of breast cancer growth by steroids and growth factors: interactions and mechanisms. Breast Cancer Res Treat 1993; 27: 57-68.
3. Wittliff JL: Steroid hormone receptors in breast cancer. Cancer 1984, 53: 630-43.
4. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 1993; 71: 1266-72.
5. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18: 387-414.
6. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995; 52: 113-33.
7. Steward AG, Westley BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by estrogen Br J Cancer 1992; 66: 640-8.
8. Actis AM, Caruso SP. Levin E: Estrogen recepto isoforms and progestin hormone dependence in a mouse mammary tumor model, Int J Cancer 1994 58: 668-71.
9. Fuqua SAW, Fitzgerald SE, Chamness GC, Tandor AK, McDonnell PD, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptoi with constitutive transcriptional activity. Cancer Res 1991; 51: 205-9.
10. Yen PM, Chin WW. Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol Endocinol 1994; 8. 450-4.
11. Raam S, Robert N, Pappas CA, Tamra H. Defective estrogen receptors in human mammary cancers: their significance in defining hormone dependence. J Nat Cancer Inst 1989; 80: 756-61.
12. Kumar V, Green S, Staub A, Chambon P: Localisation of the estrogen-binding and putative DNA-binding domains of the human estrogen receptor. EMBO J 1986, 5: 2231-6.
13. Levin E, Caruso SP, Actis AM: Factors transcripcionales y diversidad prolferativa de las células neoplasicas: Medicina Buenos Aires; 1994; 54: 589-95.
14. Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen activation via cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 1994; 91: 8517-21.
15. Bloom ND, Fishman JH: Tamoxifen treatment failures in hormonally responsive breast cancers. Correlation with steroid receptors. Cancer 199, 52: 1190-4.
16. Friedl A, Jonat W. Affinitāt des mit östradiol besetzten östrogen receptors für tamoxifen. Tumor Diagnos Ther 1988; 9: 242-6.
17. Hedden A, Müller V, Jensen EV. A new interpretation of antiestrogen action. Ann N Y Acad Sci 1995; 761: 109-20.
18. Levin E, Tomchinsky S, Lopez SJ. Displacement by tamoxifen of the estradiol-estrogen receptor binding: a functional assay for breast cancer studies. J Steroid Biochem Mol Biol 1990; 37: 681-6.
19. Levin E, Caruso S, Actis A Functional expressions of estrogen receptors in experimental and human mammary tumors. Endocrine Related Cancer 1995; 2: 111-3.
20. Lanari C, Molinolo AA, Pasqualini CD: Induction of mammary carcinomas by medroxiprogesterone acetate in BALB/c female mice. Cancer Lett 1986; 33: 215-23.
21. Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD: Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst 1987; 79: 1341-50.
22. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP: The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 1993; 90: 4441-5.
23. Cho-Chung YS, Clair T, Tortora G, Yokosaki H: Role of site selective cAMP analogues in the control and reversal of malignancy Pharmac Ther 1991; 50: 1-33.
24. Tortora G, Ciardiello F, Pepe S, Tagiaferri P, Ruggiero A, Bianco C, Guarrasi R, Miki K, Bianco AR: Phase I clinical trial with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. Clin Cancer Res 1995; 1: 377-84.
25. Actis AM, Caruso SP, Levin E: Opposite effect of a cAMP analogue on tumoral growth related to hormone dependence of a murine mammary tumor. Cancer Lett 1995; 96: 81-5.
26. Truss M, Bartsch. Schelbert A, Haché RJG, Beato M: Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J 1995; 14: 1737-51.
27. Jiang SY, Langan-Fahey SM, Stella AM, McCague R1 Jordan VC. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNA for ER. Mol Endocrinol 1992; 6: 2167-74.
28. Landel CC, Kushner PJ, Greene GL. The interaction of human estrogen receptor with DNA is modulated by receptor associated proteins. Mol Endocrinol 1994; 8: 1407-19.
29. Smith D, Toft D: Steroid receptors and their associated proteins. Mol Endocrinol 1993; 7: 4-11.
30. Metzger D, Berry M, Ali S, Chambon P Effects of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol Endocrinol 1995; 9: 579-91.
31. Brunner N, Clarke R, Lippman ME, Dickson RB. Models for studying the progression from hormone-dependency to independency in human breast cancer. In: Growth regulation of cancer. Lippman ME, Dickson RB (eds) New York. Alan Liss; 1990; 115-25.
32. Morrow M, Jordan VC: Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg 1993; 128: 1187-91.
33. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
34. Levin E, Schuarzberg P. Receptores a antiestrógenos ¿para qué sinven¿ Medicina (Buenos Aires) 1990; 50: 74-80.
35. Wolf DM, Langan Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanisms of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85: 806-12.
36. Fuqua SAW. Estrogen receptor mutagenesis and hormone resistance. Cancer 1994; 74: 1026-9.
37. Clarke R, Lippman ME: Antiestrogen resistance: mechanisms and reversal. in: Drug resistance in oncology. Teicher BA (ed) New York: Deckker; 1992, p 501-36
38. Jordan VC, Fritz NF, Langan Fahey S, Thompson M, Tormey DC. Aiteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant tamoxifen monotherapy. J Natl Cancer Inst 1991; 83: 1488-91.
39. Ree AH, Mani SK, Walaas SI, et al. Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors by phorbol ester and calcium in MCF-7 cells. Endocrinology 1991; 129: 339-44.
40. Levin E, Actis AM, Lopez S: Characterization of rat uterine estrogen receptor in vivo. J Steroid Biochem Mol Biol 1993; 37: 681-5.
41. Levenson AS, Jordan VC. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994; 51: 229-39.
42. Wats CKW, King RJB: Overexpression of estrogen receptor in HTB 96 human osteosarcoma cells results in estrogen-induced growth inhibition and receptor cross-talk. J Bone Miner Res 1994; 9: 1251-8.
43. Greenberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 1987, 47: 70-4.
44. Kiss Z. Tamoxifen stimulates phospholipase D activity by an estrogen receptor independent mechanism. FEBS Lett 1994; 355: 173-7.